NeuroScientific Biopharmaceuticals (ASX:NSB) - The evolution of cellular medicine

What separates a promising cell therapy from a clinically credible one? In Episode 1 of NSB Behind the Science, Chief Scientific Officer Dr Marian Sturm and Chief Medical Officer Professor Catherine Cole explore the evolution of cellular medicine and what it takes for emerging science to translate into meaningful therapies for patients. Drawing on decades of experience across cellular therapies, oncology and clinical medicine, they discuss: • How cellular medicine has evolved from blood and bone marrow transplantation to today’s advanced therapies • Why cell therapies present unique manufacturing, regulatory and clinical challenges • The importance of understanding mechanism of action and selecting the right patient population • Why safety, efficacy and quality of life are critical when assessing new therapies • What separates scientifically credible cellular medicine programs from more speculative approaches As cellular medicine continues to mature, strong science, disciplined development and clinical evidence will remain central to building confidence among clinicians, regulators and investors. The video covers: 00:00 – Introduction & Overview 00:24 – The Evolution of Cellular Therapies (Early Research to CAR-T) 02:08 – Key Applications: Regenerative Medicine, Immune Diseases & Cancer 04:26 – Manufacturing & Clinical Complexities of Cell Therapies 05:42 – Clinician Perspective: Chemotherapy vs. Targeted Therapies 07:44 – Public & Investor Misunderstandings of Cell-Based Therapies 08:26 – Translating Lab Research into Meaningful Patient Therapies 09:27 – What Defines a Credible Cellular Medicine Program 10:24 – Earning Clinician Confidence: Safety, Efficacy & Immune Balance About NeuroScientific Biopharmaceuticals Ltd NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company’s research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.